Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the
newer antipsychotics are risk factors for development of diabetes. Subjects with these risk
factors plus obesity and/or family history of diabetes who agree to study participation will
undergo an oral glucose tolerance test. If the oral glucose tolerance test demonstrates that
the subject is pre-diabetic (elevated glucose levels, but below the diabetic range), he/she
will have his/her insulin resistance level measured, prior to random assignment to either
stay on current antipsychotic medication or switch to ziprasidone. Insulin resistance will be
measured again after four months. The primary hypothesis is that insulin resistance will
decrease in those switched to ziprasidone relative to those continuing on their same
antipsychotic medication.
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio